UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                     FORM 25

                   NOTIFICATION OF REMOVAL FROM LISTING AND/OR
                     REGISTRATION UNDER SECTION 12(b) OF THE
                        SECURITIES EXCHANGE ACT OF 1934.





                                                Commission File Number 000-20985

             Calypte Biomedical Corporation; American Stock Exchange
    (Exact name of Issuer as specified in its charter, and name of Exchange
where security is listed and/or registered)

                         5 Centerpointe Drive, Suite 400
                            Lake Oswego, Oregon 97035
                                 (971) 204-0282

                     Common stock, par value $0.03 per share
                      (Description of class of securities)



Please place an X in the box to designate the rule provision relied upon to
strike the class of securities from listing and registration:

|_|     17 CFR 240.12d2-2(a)(1)

|_|     17 CFR 240.12d2-2(a)(2)

|_|     17 CFR 240.12d2-2(a)(3)

|_|     17 CFR 240.12d2-2(a)(4)

|_| Pursuant to 17CFR 240.12d2-2(b), the Exchange has complied with its rules to
strike the class of securities from listing and/or withdraw registration on the
Exchange.

|X| Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of
the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the
voluntary withdrawal of the class of securities from listing and registration on
the Exchange.



- --------------------------------------------------------------------------------





      Pursuant to the requirements of the Securities Exchange Act of 1934,
Calypte Biomedical Corporation certifies that it has reasonable grounds to
believe that it meets all of the requirements for filing the Form 25 and has
caused this notification to be signed on its behalf by the undersigned duly
authorized person.

                                         Calypte Biomedical Corporation


                                         By: /s/ Theodore R. Gwin
                                             --------------------
                                             Theodore R. Gwin
                                             Chief Financial Officer


Dated:     August 17, 2006